Vertex cystic fibrosis drug cocktails appear to hit the mark in trials

Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news